Tohoku University. Research Profiles

LANGUAGE
  • Top
  • Life Sciences
  • Extracorporeal Shock Wave Therapy as a New, Non-Invasive Angiogenic Therapy

Extracorporeal Shock Wave Therapy as a New, Non-Invasive Angiogenic Therapy

update:2019-01-18
  • JAPANESE
  • INQUIRY
  • seed-3-1-en.jpg
  • seed-3-2-en.jpg
  • seed-3-3-en.jpg
NEXT
PREV
Features
Extracorporeal shock wave (SW) therapy was introduced clinically more than 20 years ago to fragment kidney stones, which has markedly improved the treatment of urolithiasis. We found that a low-energy SW (about 10% of the energy density that is used for urolithiasis) effectively increases the expression of vascular endothelial growth factor (VEGF) in cultured endothelial cells. Based on this in vitro study, we have initiated in vivo studies and have demonstrated that extracorporeal cardiac SW therapy with a low-energy SW up-regulates the expression of VEGF, induces neovascularization, and improves myocardial ischemia in a porcine model of chronic myocardial ischemia, without any adverse effects in vivo. On the basis of promising results in animal studies, we performed a series of clinical studies in patients with severe coronary artery disease without indication of PCI or CABG, including, firstly, an open trial followed by a placebo-controlled, double-blind study. In both studies, our extracorporeal cardiac SW therapy improved symptoms, exercise capacity, and myocardial perfusion in patients with severe coronary artery disease. Importantly, no procedural complications or adverse effects were noted. The SW therapy was also effective in ameliorating left ventricular remodeling after acute myocardial infarction (MI) in pigs and in enhancing angiogenesis in hind-limb ischemia in rabbits. Based on these animal studies, we are also conducting clinical studies in patients with acute MI and in those with peripheral arterial disease. Thus, our extracorporeal cardiac SW therapy is an effective, safe, and non-invasive angiogenic approach in cardiovascular medicine and its indication could be extended to a variety of ischemic diseases in the near future.

Targeted Application(s)/Industry
The treatment for severe angina pectoris was approved as a highly advanced medical treatment by Ministry of Health, Labour and Welfare, Japan in 2010.
The low-energy SW therapy would be applicable to a wide range of diseases. Your inquiries about the collaborative research are always welcome.

Researchers

Department of Cardiovascular Medicine, Graduate School of Medicine

SHIMOKAWA, Hiroaki , Professor
MD, PhD

Keywords

Related Information

References
1) Nishida T, et al. Circulation.110:3055-61, 2004.
2) Fukumoto Y, et al. Coron Artery Dis. 17:63-70, 2006.
3) Uwatoku T, et al. Coron Artery Dis.18:397-404, 2007.
4) Oi K, et al. Tohoku J Exp Med. 214:151-158, 2008.
5) Shimokawa H, et al. Shock Waves 17:449-455, 2008.
6) Ito K, et al. Tohoku J Exp Med. 219:1-9,2009.
7) Kikuchi Y, et al. Circ J. 74:589-591, 2010.
8) Ito Y, et al. Coron Artery Dis. 21:304-311, 2010.
9) Ito K, et al. Am J Cardiovasc Drugs. 11:295-302, 2011.
10) Serizawa F, et al. Eur J Vasc Endovasc Surg. 42:254-260, 2011.
11) Serizawa F, et al. Circ J. 76:1486-93, 2012.
12) Hayashi D, et al. Wound Repair Regen. 20:887-95, 2012.
13) Yamaya S, et al. J Neurosurg. 2014 (in press).
List